Global Prevalence of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

Brief description of study

ATTR-CM is a condition which causes accumulation of a protein in the heart and increases risk of having heart problems. This study will explore the prevalence of ATTR-CM among patients within a clinically at risk population, those with HFpEF. This study is different from your regular medical care. The purpose of regular medical care is to improve or otherwise manage your health, but the purpose of research is to gather information to advance science and medicine and does not replace your regular medical care. The purpose of this study is to determine the presence of ATTR-CM among patients with HFpEF and to look at variations at a country, regional, and global level.


Clinical Study Identifier: s20-01805
ClinicalTrials.gov Identifier: NCT04424914
Principal Investigator: Alex Reyentovich.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.